Key result
Coronary revascularization in ICB-myocarditis is linked to ~303% higher 90-day myocarditis-related mortality.
Why the study?
ICB-associated myocarditis can present similarly to or overlap with other cardiac pathology such as acute coronary syndrome, challenging prompt clinical diagnosis.
Does coronary revascularization impact 90-day mortality in patients with ICB-myocarditis and concomitant CAD?
Observational (n=261)
Yes
Does coronary revascularization impact 90-day mortality in patients with ICB-myocarditis and concomitant CAD?
In patients with ICB-myocarditis, concomitant CAD and subsequent revascularization are associated with higher 90-day mortality, potentially due to delayed diagnosis and treatment of the myocarditis.
Answers are grounded in this paper and cite their sources.
CAD coexists in 23% of suspected ICB-myocarditis cases; observational data leaves open optimal diagnostic and revascularization strategies.
Purpose Immune-checkpoint-blocker (ICB) associated myocarditis (ICB-myocarditis) may present similarly and/or overlap with other cardiac pathology including acute coronary syndrome presenting a challenge for prompt clinical diagnosis. Methods An international registry was used to retrospectively identify cases of ICB-myocarditis. Presence of coronary artery disease (CAD) was defined as coronary artery stenosis >70% in patients undergoing coronary angiogram. Results Among 261 patients with clinically suspected ICB-myocarditis who underwent a coronary angiography, CAD was present in 59/261 (22.6%) (Table 1). Coronary revascularization was performed during the index hospitalization in 19/59 (32.2%) patients. Patients undergoing coronary revascularization less frequently received steroids administration within 24h of admission compared to the other groups (p=0.029). Myocarditis related 90-day mortality was 9/17 (52.7%) in the revascularized cohort, compared to 5/31 (16.1%) in those not revascularized and 25/156 (16.0%) in those without CAD (p=0.001). irAE-related 90-day mortality was 9/17 (52.7%) in the revascularized cohort, compared to 6/31 (19.4%) in those not revascularized and 31/156 (19.9%) in no CAD groups (p=0.007) (Figure 1). All-cause 90-day mortality was 11/17 (64.7%) in the revascularized cohort, compared to 13/31 (41.9%) in no revascularization and 60/158 (38.0%) in no CAD groups (p=0.10). After adjustment on age and sex, coronary revascularization remained associated with ICB-myocarditis-related death at 90 days (Hazard ratio [HR]=4.03, 95%confidence interval [CI] 1.84–8.84, p<0.001) and was marginally associated with all-cause death (HR=1.88, 95% CI 0.98–3.61, p=0.057). Conclusion CAD may exist concomitantly with ICB-myocarditis and portend a poorer outcome when revascularization is performed. This is potentially mediated thru delayed diagnosis and treatment or more severe presentation of ICB-myocarditis.
No takes yet. Share an insight, caveat, or question.
Nowatzke et al. (2022) conducted an observational in Immune-checkpoint-blocker associated myocarditis (n=261). Coronary revascularization vs. No revascularization was evaluated on ICB-myocarditis-related death at 90 days (HR 4.03, 95% CI 1.84-8.84, p=<0.001). Coronary revascularization in patients with ICB-myocarditis was associated with a higher risk of myocarditis-related death at 90 days.
Synapse has enriched 10 related papers. Consider them for comparative context: